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http://www.biomedcentral.com/1471-2407/14/337RESEARCH ARTICLE Open AccessHealth-related quality of life and risk of colorectal
cancer recurrence and All-cause death among
advanced stages of colorectal cancer 1-year after
diagnosis
Carlos KH Wong1*, Wai-Lun Law2, Yuk-Fai Wan1, Jensen Tung-Chung Poon2 and Cindy Lo-Kuen Lam1Abstract
Background: The study aimed to examine the association between health-related quality of life (HRQOL) assessed
with overall survival (OS) and recurrence after diagnosis of colorectal cancer (CRC).
Methods: Overall 160 patients with advanced stage CRC were recruited in an observational study and completed
the generic and condition-specific HRQOL questionnaires at the colorectal specialist outpatient clinic in Hong Kong,
between 10/2009 and 07/2010. Socio-demographic and clinical characteristics including duration since diagnosis,
primary tumor location and treatment modality, were collected to serve as predictor variables in regression models.
All-cause death or CRC recurrence was the event of interest. Association between HRQOL with OS was assessed
using Cox regression. Association between HRQOL and CRC recurrence was further modeled by competing-risks
regression adjusted for the competing-risks of death from any cause.
Results: After a median follow-up of 23 months, there were 22 (16.1%) incidents of CRC recurrence and 15 (9.4%)
deaths. Decreased physical functioning (hazard ratios, HR = 0.917, 95% CI:0.889-0.981) and general health of domains
in SF-12 (HR = 0.846, 95% CI:0.746-0.958) or SF-6D scores (HR = 0.010, 95% CI:0.000-0.573) were associated with an
increased risk of death, with adjustment of patients’ characteristics. Increased vitality (HR = 1.151, 95% CI:1.027-1.289)
and mental health (HR = 1.128, 95% CI:1.005-1.265) were associated with an increased likelihood of death. In models
adjusted for competing-risk of death, those with worse HRQOL was not associated with increased risk of CRC recurrence.
Conclusions: Although self-reported HRQOL was not a significant prognostic factor for CRC recurrence, the HRQOL
provided independent prognostic value about mortality in patients with advanced stage of CRC.
Keywords: Quality of life, Colorectal cancer, Prognosis, Survival, Recurrence, Competing risksBackground
Colorectal cancer (CRC) is one of the most life-threatening
cancers worldwide [1]. The estimated five-year relative
survival rate of US patients with CRC was 69.5% for
stage III and 11.3% for stage IV after adjustment for age
[2]. The prognosis indicated by overall survival (OS) is
primarily dependent on the stage of cancer. According
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stage of cancer is when the carcinoma reaches any
regional lymph nodes or has confirmed distant metasta-
sis. In addition to clinical factors that influence the risk
of mortality such as cancer stage [4,5], patients’ self-
reported health-related quality of life (HRQOL) acts as
the complementary biomedical indicator in clinical
decision-making regarding the choice of therapeutic
modalities due to the strong association between some
aspects of HRQOL and OS [5-7].
Not only do the survivors of CRC patients at one year
after diagnosis face the risk of mortality, but those with
advanced stage of cancer also face the threat of cancertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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measure was associated with the risk of CRC recur-
rence remains uncertain and this measure was investi-
gated in patients with breast cancer only [8,9]. To date,
only one study investigated the associations between
clinical characteristics and the risk of CRC recurrence
after accounting for competing-risks of death from any
cause [10], acknowledging that patients dying from any
cause were no longer at risk of CRC recurrence other
than censoring all-cause mortality in conventional
approach. The aims of this study were to examine the
association between HRQOL data and the risk of
all-cause mortality using Cox regression approach, and
the association between HRQOL and the risk of CRC
recurrence using competing-risks regression approach
in patients with advanced stage of CRC after control-
ling for the socio-demographic and clinical variables.
Methods
Subjects
This study was part of a sequence of studies using the
health survey data to examine the HRQOL profile and
health preference scores of Chinese patients with colo-
rectal polyp/cancer [11-16]. Study data were retrieved
from the 647 adult patients recruited at the colorectal
specialist outpatient clinic of Queen Mary Hospital in
Hong Kong between October 2009 and July 2010.
Survival analysis was conducted to select the eligible
patients who had advanced stages of colorectal cancer,
stage III and IV as defined by AJCC cancer stage clas-
sification [3], at the initial diagnosis. Eligibility criteria
of subjects were histologically confirmed by colorectal
surgeons (WL Law and JTC Poon). Among 536 patients
(response rate of 82.8%) completed the baseline survey,
condition-specific Functional Assessment of Cancer
Therapy-Colorectal (FACT-C) and generic SF-12 and
SF-6D Health Survey were administered to 160 eligible
patients (Stage III: 115, 71.9%; Stage IV: 45, 28.1%) by
a trained research assistant after written consent was
obtained. At baseline assessment, socio-demographic
characteristics were obtained from the patients, whereas
their clinical variables including duration since diagno-
sis of CRC, primary tumor location (Colon/Sigmoid vs
Rectum), current CRC related treatment, cancer stage
(Stage III vs Stage IV), presence of stoma (Permanent/
Temporary vs Not even/Closure), and presence of prior
CRC recurrence were retrieved from electronic medical
record. Survival status was censored on the date of the
last follow-up or on 14 August 2012.
Ethical approval was obtained from The University of
Hong Kong/Hospital Authority Hong Kong West Cluster
institutional review board (HKU/HA HKW IRB #UW
09–391), and this trial was registered with Hong Kong
Clinical Trial Register (#HKCTR-973, Trial RegistrationDate: 6 Oct 2009) and Clinicaltrial.gov (#NCT02038283,
Trial Registration Date: 28 August 2013).
HRQOL measures
Functional assessment of cancer therapy-colorectal (FACT-C)
The FACT-C is a 34-item condition-specific HRQOL
measure that covers a range of important aspects of
quality of life in relation to patients with CRC. It
assesses HRQOL across five subscales (physical well-
being, PWB; social well-being, SWB; emotional well-
being, EWB; functional well-being, FWB; and colorectal
cancer subscale, CCS) each with five response options
(“not at all”, “a little bit”, “somewhat”, “quite a bit”, and
“very much”). The raw scores are computed to give
standard scores in the possible range of 0–28 for PWB,
EWB, FWB, and CCS subscales and 0–24 for SWB sub-
scale. Higher subscale scores indicate better HRQOL. Pre-
vious studies have reported the psychometric properties
regarding the validity and reliability of the instrument used
in Chinese patients with colorectal neoplasms [15,17,18].
SF-12 health survey
The SF-12 is a widely used generic HRQOL measure
assessing eight subscales (physical functioning, PF; role
physical, RP; bodily pain, BP; general health, GH; vitality,
VT; social functioning, SF; role emotional, RE; and mental
health, MH). The theoretical range of the subscale and
summary scores are from 0 to 100, with higher scores in-
dicating better HRQOL. Psychometric properties of SF-12
have been examined in Chinese populations [19].
SF-6D health survey
The SF-6D is used as a generic preference-based meas-
ure assessing health across six dimensions (physical
functioning, role limitations, social functioning, pain,
mental health, and validity) with 3–5 response options.
The theoretical range of SF-6D score is between 0.315
(worst possible health state) and 1 (perfect health) based
on the Chinese Hong Kong scoring algorithm [20,21].
Statistical analysis
Baseline socio-demographic and clinical characteristics
of patients with different cancer stages (Stage III versus
Stage IV) were compared using Chi-square test for cat-
egorical variables and Mann Whitney U-test for continu-
ous variables. Mean scores and standard deviation of the
scale in each instrument were calculated according to
their official scoring algorithm. Since scoring algorithm
of each instrument did not include guideline to deal with
missing data, subjects with missing data in one of the in-
strument items were excluded in this study. Independent
t-test was used to compare the differences in HRQOL
scores between clinical characteristics. To retain the
maximum information of the data, all HRQOL scores
Figure 1 Overall Survival (months) of 160 colorectal cancer
patients.
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rather than categorical variables [22].
Our event of interest was taken as 1) death from any
cause or 2) CRC recurrence. Correspondingly, the pri-
mary objective of this study was to examine the associa-
tions between HRQOL, death and incidence of CRC
recurrence accounting for the competing-risk of death
from any cause. The survival duration was cumulated
from the first month after completion of the survey.
Each patient was observed from the date of recruitment
to the study until the occurrence of CRC recurrence,
death from any cause as the competing event, or date of
last follow-up as censoring. Survival curves were esti-
mated by Kaplan-Meier method and their differences be-
tween cancer stages were compared using the log-rank
test. Univariate and multivariate Cox proportional haz-
ards regression models were performed to estimate the
associations between patients’ characteristics, repre-
sented by fixed-in-time variables, and HRQOL scores
with the dependent variable of CRC recurrence or death
from any cause. Three separate multivariate Cox models
were fitted by assigning the independent variable of
HRQOL as 1) FACT-C subscale scores, 2) the SF-12 do-
main scores, and 3) the SF-6D score. Hazard ratio (HR)
and its 95% confidence intervals were reported for each
variable in the regression models. Prior analysis alterna-
tively modeled the effects of prognostic factors on all-
cause mortality using competing-risks regression with
censoring on recurrence [10]. However, the underlying
assumption of random censoring was violated in such
circumstance [10], and current analysis avoided the
problem when the survived patients were censored at
the time of loss to follow-up or data extraction date.
Therefore, OS was defined as the time interval between
the date when a patient was recruited to the study and
the date of death from any cause/last follow-up.
Due to the fact that patients who died from any cause
was impossible to have event of interest occurred, death
from any cause acted as the competing event. To ac-
count for the competing-risks of death, competing-risks
regression models based on Fine and Gray [23] were
fitted to measure the association between patients’ char-
acteristics and HRQOL on risk of CRC recurrence. This
model further excluded 23 subjects who had a prior
CRC recurrence before the baseline assessment. Sensitiv-
ity analysis was also conducted using conventional Cox
regression analysis to examine the effect of patients’
characteristics and HRQOL on risk of CRC recurrence.
Predictive accuracy of Cox models was assessed and
compared using Harrell’s discrimination C-index, ran-
ging from zero to one. A value of 0.5 indicates no pre-
dictive discrimination, and values of 0 or 1.0 indicate
perfect separation of subjects with different outcomes
[24]. Goodness-of-fit for both Cox and competing-riskregression models were assessed using Akaike information
criterion (AIC) and Bayesian information criterion (BIC).
All regressions and other analyses were conducted using
STATA version 12. In particular, competing-risks regres-
sion was estimated using STATA command stcrreg.
Results
At baseline, median age of patients was 62 years and
55.0% were male patients. The primary tumors were
mostly (56.3%) located in colon. Among 160 patients
with advanced CRC, there were 22 (16.1%) incidences of
CRC recurrence and 15 (9.4%) deaths until the censored
date in August 2012. Of those who died, there were 7
(50%) incidences of CRC recurrence between the base-
line date and the death date. The majority (137, 85.6%)
of patients with CRC did not have prior history of CRC
recurrences whereas the remaining 23 patients did: 11
with liver metastasis, 2 with lung and liver metastasis,
and 10 with other disease progressions. The survival dis-
tribution for the death from any cause and CRC recur-
rence are shown in Figures 1 and 2. Table 1 describes
the baseline socio-demographic characteristics of pa-
tients with advanced CRC. Socio-demographic charac-
teristics were compared between patients with
different stages of CRC. Patients with stage IV CRC
were more likely to be working-free or non-smokers
than those with stage III CRC. Patients with stage IV
CRC were more likely to be on CRC related treatment
and recurrence than those with stage III CRC. Other
socio-demographic and clinical characteristics were
similar in patients with different cancer stages.
Table 2 presents the baseline HRQOL scores in pa-
tients with or without CRC recurrence, or who were
Figure 2 Colorectal cancer recurrence control (months) of 137
CRC patients without prior CRC recurrence.
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role physical scores were more likely to have recurrent
CRC (P = 0.006) whereas those with greater physical
functioning, role physical or general health were more
likely to stay alive (P = 0.004; P = 0.007; P = 0.011, re-
spectively). There were no significant differences in all
the five subscales of FACT-C instrument between vital
status group and CRC recurrence group. The SF-6D
score differed significantly in the alive and death patients
(P = 0.019) but there was no significant difference be-
tween patients with or without CRC recurrence.
Table 3 demonstrates the results of univariate and multi-
variate Cox regression adjusted for socio-demographic
and clinical characteristics. Univariate Cox regression indi-
cated that a decrease in PF (HR = 0.975, 95% CI = 0.960-
0.991, P = 0.003), RP (HR = 0.975, 95% CI = 0.956-0.994,
P = 0.009), and GH (HR = 0.970, 95% CI = 0.948-0.992,
P = 0.008) domains in SF-12 and SF-6D scores (HR =
0.007, 95% CI = 0.000-0.273, P = 0.008) was associated
with poorer survival. All five FACT-C subscale scores and
none of the socio-demographic and clinical characteristics
at baseline were associated with OS. After adjustment for
socio-demographic and clinical characteristics, the HR
of five FACT-C subscale scores were also not signifi-
cantly associated with OS with the C-statistic of 0.824
(95% CI = 0.681-0.968) but the statistical associations
between HRQOL and all-cause mortality were signifi-
cant in the SF-6D score (HR = 0.010, 95% CI = 0.000-
0.573, P = 0.026) and some subscale scores of SF-12.
The MH and VT subscales become significantly associated
with OS after inclusion of HRQOL and other confounding
variables, whereas the PF and GH were statistically signi-
ficant in both univariate and multivariate analyses. The
VT (HR = 1.151, 95% CI = 1.027-1.289, p = 0.015) and MH
(HR = 1.128, 95% CI = 1.005-1.265, p = 0.040) were posi-
tively associated with the likelihood of death.Table 4 shows the results of univariate and multivari-
ate competing-risks regression adjusted for socio-demo-
graphic and clinical characteristics. Univariate analysis
found that metastatic CRC, greater role functioning or
SF-6D scores was associated with higher risk of CRC
recurrence. After adjustment for socio-demographic
and clinical characteristics, no measures of HRQOL
were detected statistically significant. Figure 3 shows
that patients with cancer stage III had significantly
higher risk of CRC recurrence than those with cancer
stage IV (log-rank test, p < 0.001). The sensitivity ana-
lysis found that the results of conventional Cox regres-
sion were similar to those of competing-risk regression
(results not shown).
Discussion
To the best of our knowledge, this was the first study to
examine the association between HRQOL and the risk
of mortality or CRC recurrence concurrently in patients
with advanced stages of CRC. The prognostic value of
HRQOL is considered important in predicting all-cause
mortality. The Cox regression analysis found that SF-12
physical functioning, general health, vitality and mental
health assessed at baseline were significantly associated
with the risk of mortality. Fitting a survival model with
clinical characteristics in conjunction with SF-12 data
achieved better predictive accuracy and goodness-of-fit
(C-statistic: 0.956; AIC: 111.2; BIC: 179.8) than models
with FACT-C (C-statistic: 0.824; AIC: 128.2; BIC: 187.3)
or SF-6D scores (C-statistic: 0.799; AIC: 131.4; BIC:
179.1). The use of competing-risks regression showed
that no measures of HRQOL were associated with CRC
recurrence, although univariate analyses detected statis-
tically significant association in role functioning and
SF-6D scores. The HRQOL data failed to improve the
prediction of CRC recurrence. Despite insignificant asso-
ciations between HRQOL and the risk of recurrence,
incorporation of HRQOL assessments in routine clinical
practice could provide important information about all-
cause mortality in patients with advanced stage of CRC
and have specialist outpatient consultation at one year
after diagnosis.
Although the prediction of OS measured by FACT-C
was not observed in this study, the majority of the exist-
ing literature reported the association between OS and
HRQOL based on condition-specific measures devel-
oped by EORTC such as QLQ-C30 and QLQ-CR38. In
previous studies of patients with any stages of CRC,
strong evidence suggested that an increase in some
functional scales measured by QLQ-C30 were associ-
ated with decreased risk of death in patients with CRC.
Better social functioning score of QLQ-C30 was associated
with improved OS among patients with metastatic
colorectal cancer [6]. The prognostic value of social
Table 1 Socio-demographic and clinical characteristics of patients with advanced stage of CRC
AJCC Stage classification
Characteristics Stage III (n = 115) Stage IV (n = 45) Total (n = 160) P-value
Age (Year,median, interquartile range) 62 (54–71) 62 (55–74) 62 (54–72) 0.301
Sex (%) 0.536
Male 56.5% 51.1% 55.0%
Female 43.5% 48.9% 45.0%
Education level (%) 0.939
No formal school 12.4% 11.1% 12.0%
Primary 30.1% 26.7% 29.1%
Secondary 43.4% 48.9% 44.9%
Tertiary 14.2% 13.3% 13.9%
Marital status (%) 0.942
Married 76.1% 75.6% 75.9%
Not married 23.9% 24.4% 24.1%
Currently working (%) 0.002a
Yes 29.2% 6.7% 22.8%
No 70.8% 93.3% 77.2%
Income (%) 0.075
≤HKD$20,000 78.4% 90.7% 81.8%
>HKD$20,000 21.6% 9.3% 18.2%
Smoking (%) 0.016a
Ever had 17.7% 35.6% 22.8%
Never had 82.3% 64.4% 77.2%
Drinking (%) 0.247
Ever had 26.3% 35.6% 28.9%
Never had 73.7% 64.4% 71.1%
Primary tumour site (%) 0.191
Colon 53.0% 64.4% 56.3%
Rectum 47.0% 35.6% 43.8%
Active CRC treatment (%) <0.001a
No 80.7% 35.6% 67.9%
Yes 19.3% 64.4% 32.1%
Stoma (%) 0.112
Present 10.5% 20.0% 13.2%
Absent 89.5% 80.0% 86.8%
Time since diagnosis (month,median, interquartile range) 31 (13–59) 23 (11–52) 27 (12–58) 0.165
Vital status (%) 0.093
Alive 93.0% 84.4% 90.6%
Death 7.0% 15.6% 9.4%
Follow-up Month for Alive (median, interquartile range) 23 (21–25) 24 (23–26) 23 (22–25) 0.088
Follow-up Month for Death (median, interquartile range) 21 (18–24) 24 (18–26) 21 (18–25) 0.336
Follow-up Month for Total (median, interquartile range) 23 (21–25) 24 (22–26) 23 (21–25) 0.750
CRC recurrenceb (%) <0.001a
Yes 10.2% 37.9% 16.1%
No 89.8% 62.1% 83.9%
Note: AJCC=American Joint Committee on Cancer.
aSignificant differences (P<0.05) between groups by Mann-Whitney U-test or by Chi-square test, as appropriate.
bExcluded 23 subjects who had a prior CRC recurrence before the baseline assessment.
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Table 2 Health-related Quality of Life in different levels of clinical characteristics
Clinical
characteristics
FACT-Cc SF-12c
PWB SWB EWB FWB CCS PF RP BP GH VT SF RE MH SF-6Dc
Overall 25.2 ± 3.8 20.2 ± 4.2 21.0 ± 3.1 18.7 ± 4.0 21.6 ± 3.4 75.2 ± 29.9 72.5 ± 27.8 84.2 ± 25.2 52.2 ± 26.6 66.0 ± 17.9 77.2 ± 30.4 88.6 ± 19.9 80.1 ± 14.7 0.81 ± 0.13
AJCC Stage
Stage III (n = 115) 25.5 ± 3.3 20.0 ± 4.4 21.1 ± 3.0 19.0 ± 4.1 21.3 ± 3.4 75.7 ± 30.5 74.2 ± 26.4 83.8 ± 25.9 52.4 ± 26.2 65.7 ± 17.8 78.8 ± 29.4 89.6 ± 18.3 80.1 ± 14.3 0.82 ± 0.13
Stage IV (n = 45) 24.5 ± 4.6 20.5 ± 3.8 20.9 ± 3.3 18.1 ± 3.9 22.3 ± 3.3 73.9 ± 28.7 68.6 ± 30.9 85.0 ± 23.5 51.8 ± 27.8 66.7 ± 18.5 73.3 ± 32.6 86.1 ± 23.3 80.0 ± 15.9 0.79 ± 0.14
P-value 0.142 0.536 0.720 0.238 0.123 0.733 0.264 0.792 0.899 0.767 0.313 0.321 0.964 0.225
Primary Tumour Site
Colon (n = 90) 25.5 ± 3.4 20.5 ± 3.7 21.2 ± 3.0 18.6 ± 4.2 22.2 ± 2.9 77.6 ± 29.7 73.7 ± 26.6 84.6 ± 25.5 53.5 ± 28.4 67.2 ± 18.1 79.1 ± 29.4 87.8 ± 20.6 82.3 ± 13.2 0.81 ± 0.13
Rectum (n = 70) 24.9 ± 4.2 19.7 ± 4.8 20.7 ± 3.2 18.8 ± 3.8 20.9 ± 3.8 71.9 ± 30.0 70.9 ± 29.5 83.6 ± 24.9 50.5 ± 24.1 64.5 ± 17.7 74.6 ± 31.7 89.6 ± 19.1 77.1 ± 16.1 0.81 ± 0.13
P-value 0.346 0.214 0.296 0.809 0.023a 0.246 0.545 0.811 0.493 0.364 0.375 0.574 0.035a 0.873
Current Treatment
Yes (n = 51) 25.9 ± 3.1 20.1 ± 4.0 21.0 ± 3.0 19.1 ± 3.9 21.8 ± 3.3 78.3 ± 30.5 76.4 ± 25.6 84.5 ± 24.0 55.6 ± 26.1 68.0 ± 16.7 82.0 ± 27.1 89.3 ± 18.0 80.0 ± 14.7 0.83 ± 0.12
No (n = 108) 23.9 ± 4.6 20.3 ± 4.7 21.0 ± 3.1 18.0 ± 4.3 21.2 ± 3.5 69.0 ± 27.9 64.8 ± 30.6 83.5 ± 27.5 45.4 ± 26.5 62.0 ± 19.7 67.5 ± 34.3 87.3 ± 23.3 80.3 ± 15.0 0.77 ± 0.14
P-value 0.003a 0.797 0.937 0.113 0.301 0.074 0.015a 0.819 0.026a 0.053 0.005a 0.564 0.922 0.010a
Stoma
Yes (n = 21) 24.8 ± 3.1 20.2 ± 4.9 20.7 ± 3.8 17.2 ± 2.8 20.7 ± 4.4 71.3 ± 24.7 60.6 ± 27.3 75.0 ± 26.9 49.3 ± 24.3 61.3 ± 17.2 61.3 ± 31.9 89.4 ± 20.0 76.9 ± 19.6 0.77 ± 0.09
No (n = 138) 25.3 ± 3.9 20.1 ± 4.1 21.1 ± 3.0 18.9 ± 4.2 21.8 ± 3.2 75.8 ± 30.6 74.3 ± 27.5 85.6 ± 24.7 52.7 ± 27.0 66.7 ± 18.0 79.6 ± 29.5 88.5 ± 20.0 80.6 ± 13.8 0.82 ± 0.14
P-value 0.545 0.928 0.580 0.074 0.185 0.531 0.040a 0.080 0.596 0.204 0.011a 0.849 0.296 0.181
Vital Status
Alive (n = 145) 25.3 ± 3.8 20.4 ± 3.9 21.0 ± 3.1 18.9 ± 4.1 21.6 ± 3.4 77.4 ± 29.0 74.4 ± 27.5 84.6 ± 24.5 54.0 ± 26.0 65.8 ± 17.4 78.3 ± 29.8 88.6 ± 20.4 79.7 ± 14.7 0.82 ± 0.13
Death (n = 15) 24.5 ± 3.6 18.1 ± 6.3 20.8 ± 2.9 17.2 ± 3.6 21.9 ± 2.9 53.6 ± 30.8 53.6 ± 24.2 80.4 ± 31.3 35.0 ± 27.0 67.9 ± 22.8 66.1 ± 34.8 88.4 ± 15.1 83.9 ± 15.1 0.73 ± 0.12
P-value 0.424 0.064 0.837 0.137 0.750 0.004a 0.007a 0.554 0.011a 0.685 0.152 0.970 0.306 0.019a
CRC Recurrenceb
Yes (n = 22) 24.3 ± 5.5 20.9 ± 5.1 20.2 ± 3.7 18.8 ± 3.1 22.0 ± 3.4 67.0 ± 27.2 57.4 ± 26.9 79.5 ± 29.5 51.8 ± 25.7 65.9 ± 23.8 68.2 ± 32.9 91.5 ± 19.0 83.5 ± 19.0 0.77 ± 0.13
No (n = 115) 25.6 ± 3.4 20.2 ± 4.0 21.2 ± 2.9 18.7 ± 4.4 21.4 ± 3.5 78.5 ± 29.2 75.0 ± 27.2 85.1 ± 24.6 53.4 ± 26.2 67.0 ± 16.7 80.2 ± 29.4 88.3 ± 20.0 80.0 ± 14.2 0.82 ± 0.13
P-value 0.151 0.501 0.149 0.925 0.449 0.091 0.006a 0.350 0.791 0.801 0.090 0.499 0.315 0.073
Note: AJCC = American Joint Committee on Cancer.
FACT-C subscales: PWB = physical well-being; SWB = social well-being; EWB = emotional well-being; FWB = functional well-being; CCS = colorectal cancer subscale;
SF-12 subscales: PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH =mental health.
aSignificant differences (P < 0.05) between groups by independent t-test.
bExcluded 23 subjects who had a prior CRC recurrence before the baseline assessment.
cHigher scores represent a higher level of functioning or a better HRQOL.
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Table 3 Crude and adjusted hazard ratio (95% CI) of risk factors for death by univariate and multivariate cox regression analysis
Crude HRa Adjusted HR
(FACT-C domain)a
Adjusted HR
(SF-12 domain)a
Adjusted HR (SF-6D)a
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
Primary Tumour Site (Colon)
Rectum 1.213 (0.438,3.361) 0.710 1.033 (0.233,4.589) 0.966 0.561 (0.054,5.855) 0.629 0.720 (0.212,2.454) 0.600
Active CRC Treatment (No)
Yes 1.633 (0.569,4.682) 0.362 1.039 (0.195,5.529) 0.964 0.424 (0.052,3.432) 0.421 1.007 (0.239,4.243) 0.993
Stoma (Present)
Absent 0.812 (0.181,3.644) 0.785 1.714 (0.212,13.840) 0.613 0.046 (0.000,4.874) 0.195 1.165 (0.189,7.168) 0.869
Time Since Diagnosis, months 0.993 (0.974,1.011) 0.427 0.998 (0.976,1.020) 0.839 1.015 (0.992,1.040) 0.199 1.003 (0.983,1.023) 0.801
AJCC (Stage III)
Stage IV 1.898 (0.688,5.242) 0.216 1.928 (0.365,10.193) 0.440 2.791 (0.319,24.446) 0.354 1.659 (0.371,7.411) 0.508
FACT-C
PWB 0.966 (0.862,1.083) 0.557 1.076 (0.857,1.352) 0.527
SWB 0.908 (0.820,1.006) 0.066 1.011 (0.870,1.174) 0.889
EWB 0.965 (0.825,1.129) 0.657 0.929 (0.683,1.264) 0.639
FWB 0.905 (0.819,1.001) 0.053 0.902 (0.722,1.128) 0.365
CCS 1.008 (0.862,1.179) 0.921 0.996 (0.796,1.247) 0.972
SF-12
PF 0.975 (0.960,0.991) 0.003b 0.917 (0.852,0.986) 0.019b
RP 0.975 (0.956,0.994) 0.009b 0.996 (0.944,1.051) 0.882
BP 0.994 (0.976,1.013) 0.552 1.055 (1.000,1.113) 0.052
GH 0.970 (0.948,0.992) 0.008b 0.846 (0.746,0.958) 0.009b
VT 1.005 (0.976,1.034) 0.754 1.151 (1.027,1.289) 0.015b
SF 0.987 (0.972,1.003) 0.109 1.015 (0.970,1.063) 0.523
RE 1.001 (0.975,1.027) 0.944 0.983 (0.919,1.051) 0.617
MH 1.016 (0.975,1.058) 0.457 1.128 (1.005,1.265) 0.040b
SF-6D 0.007 (0.000,0.273) 0.008b 0.010 (0.000,0.573) 0.026b
AIC 128.2 111.2 131.4
BIC 187.3 179.8 179.1
Harrell’s C-statistic 0.824 (0.681,0.968) 0.956 (0.909,1.002) 0.799 (0.678,0.921)
Note: HR = Hazard ratio.
FACT-C subscales: PWB = physical well-being; SWB = social well-being; EWB = emotional well-being; FWB = functional well-being; CCS = colorectal cancer subscale;
SF-12 subscales: PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH =mental health.
aHR > 1 indicates greater risk for death, with adjustment of socio-demographic characteristics.
bp-value < 0.05.
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Table 4 Crude and adjusted hazard ratio (95% CI) of risk factors for CRC recurrence by univariate and multivariate competing-risks regression analysis
Crude SHRa Adjusted SHR
(FACT-C domain)a
Adjusted SHR
(SF-12 domain)a
Adjusted SHR (SF-6D)a
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
Primary Tumour Site (Colon)
Rectum 1.173 (0.513,2.682) 0.705 1.084 (0.152,7.754) 0.936 1.419 (0.149,13.555) 0.761 1.121 (0.256,4.912) 0.880
Active CRC Treatment (No)
Yes 3.891 (1.663,9.102) 0.002b 4.724 (0.812,27.477) 0.084 2.871 (0.824,10.006) 0.098 2.424 (0.771,7.617) 0.130
Stoma (Present)
Absent 0.474 (0.179,1.254) 0.133 0.375 (0.078,1.814) 0.223 0.864 (0.145,5.159) 0.873 0.845 (0.205,3.484) 0.815
Time Since Diagnosis, months 0.984 (0.963,1.006) 0.152 0.998 (0.974,1.023) 0.892 1.002 (0.985,1.019) 0.817 0.992 (0.970,1.014) 0.481
AJCC (Stage III)
Stage IV 4.002 (1.777,9.016) <0.001b 2.469 (0.413,14.743) 0.322 6.225 (1.144,33.866) 0.034b 3.965 (1.222,12.862) 0.022b
FACT-C
PWB 0.949 (0.890,1.011) 0.103 0.925 (0.765,1.119) 0.424
SWB 1.042 (0.899,1.208) 0.583 1.067 (0.842,1.352) 0.593
EWB 0.925 (0.831,1.029) 0.152 0.880 (0.702,1.102) 0.265
FWB 1.001 (0.930,1.077) 0.988 1.022 (0.847,1.233) 0.821
CCS 1.059 (0.921,1.217) 0.420 1.281 (0.980,1.674) 0.069
SF-12
PF 0.989 (0.978,1.000) 0.053 1.001 (0.970,1.033) 0.950
RP 0.981 (0.968,0.994) 0.005b 0.972 (0.945,1.001) 0.058
BP 0.993 (0.978,1.009) 0.398 0.992 (0.958,1.028) 0.663
GH 0.998 (0.983,1.013) 0.770 1.002 (0.972,1.034) 0.877
VT 0.998 (0.972,1.024) 0.852 1.009 (0.966,1.054) 0.690
SF 0.989 (0.978,1.001) 0.070 1.008 (0.981,1.035) 0.569
RE 1.008 (0.980,1.036) 0.579 1.036 (0.967,1.110) 0.319
MH 1.015 (0.973,1.059) 0.478 1.028 (0.977,1.082) 0.286
SF-6D 0.057 (0.004,0.888) 0.041b 0.503 (0.022,11.259) 0.665
AIC 187.4 202.5 199.4
BIC 243.5 267.5 244.7
Note: SHR = Sub-Hazard ratio.
FACT-C subscales: PWB = physical well-being; SWB = social well-being; EWB = emotional well-being; FWB = functional well-being; CCS = colorectal cancer subscale;
SF-12 subscales: PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH =mental health.
aSHR > 1 indicates greater risk for CRC recurrence, with adjustment of socio-demographic characteristics.
bp-value < 0.05.
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Figure 3 Colorectal cancer recurrence control (months) of 137
CRC Patients stratified by AJCC Stage (Stage III, n = 108;
Stage IV, n = 29).
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samples from ten countries [25]. For metastatic patients
treated with oxaliplatin-based first line chemotherapy,
baseline physical functioning score was independently
associated with the OS [26]. Baseline measurement of
HRQOL including four functional scales (physical func-
tioning, role functioning, social functioning and emo-
tional functioning), global QOL and four symptom
scales (nausea and vomiting, pain, dyspnoea and sleep
disturbance) of QLQ-C30 had a significant association
with the survival of patients with advanced CRC and at
the commencement of receiving chemotherapy [5]. OS
was predicted by the change in QLQ-C30 physical func-
tioning, social functioning, appetite loss and global
QOL scale scores from baseline to three months after
treatment in the advanced stage of CRC [27]. For patients
with rectal cancer, physical functioning, nausea and vomit-
ing of QLQ-C30 and sexual enjoyment of QLQ-CR38 pre-
dicted the one-year survival after surgery [28]. In contrary
to aforementioned studies, our findings found no associ-
ation between the condition-specific measures and the risk
of mortality or CRC recurrence.
Furthermore, the HRQOL assessed by non-EORTC in-
struments was found to be an independent predictor of
survival. In a treatment clinical trial for patients with colo-
rectal hepatic metastasis, longer OS was associated with
higher physical scales of Rotterdam Symptom Checklist at
baseline and lower deterioration in physical scales over
time [29-31]. In an extension to all stages of colorectal
cancer, health and physical subscales measured by the
Quality of Life Index were prognostic measures of survival
[32]. Meanwhile, pretreatment pain intensity scores mea-
sured by Brief Pain Inventory was a good prognostic factor
of OS in patients with locally recurrent rectal cancer [7].
In line with previous studies using generic HRQOL mea-
sures, this study also found that greater physical function-
ing was associated with longer OS.Limitation
There were several limitations in this study. Firstly, the
current study did not consider the regional lymph node
ratio which was identified as one of the major prognostic
factors in longitudinal studies [4,33-35]. Secondly, rates
of all-cause mortality and recurrence reported in current
study may be higher than those in other studies
conducted in Chinese population [36,37], especially in
studies of CRC patients undergoing curative open or
laparoscopic resections. Patients in current study were
recruited at specialist outpatient clinic where they were
followed up at one year after diagnosis rather than a
short period away from diagnosis or surgery. Thirdly,
the total number of samples might be insufficient to
check for internal validation by splitting baseline data
into two or more portions. Apart from internal valid-
ation, future interesting work on an external validation
utilizing an independent set of CRC data was warranted
to strengthen the validity of model interpretation [22].
Conclusion
To conclude, it was feasible to predict the OS through the
assessment of generic HRQOL measure in the first year
after diagnosis of advanced CRC. Although self-reported
HRQOL was not a significant prognostic factor for CRC
recurrence, the HRQOL measured by SF-12 instrument
provided independent prognostic value and information
about mortality in patients with advanced stage of CRC.
This added-value of the HRQOL in conjunction with clin-
ical characteristics may help in decision-making in clinical
practice.
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